Market Place
Sourcing Support
Report from Extraordinary General Meeting in LIDDS
11 Mar 2022 //
GLOBENEWSWIRE
LIDDS publishes agenda for the company`s Capital Markets Day 2022
04 Mar 2022 //
GLOBENEWSWIRE
Statement from LIDDS regarding convertible note agreement
24 Feb 2022 //
GLOBENEWSWIRE
LIDDS AB (publ) Year-end report 2021
23 Feb 2022 //
GLOBENEWSWIRE
LIDDS secures financing of 40.8 MSEK to create foundation for new partnerships
22 Feb 2022 //
GLOBENEWSWIRE
LIDDS Next Step with NanoZolid formulated docetaxel
21 Feb 2022 //
GLOBENEWSWIRE
LIDDS announces positive topline results from the phase I study of NanoZolid
29 Dec 2021 //
GLOBENEWSWIRE
LIDDS Announces Appointment of Matthew Lindon as Chief Scientific Officer
20 Dec 2021 //
GLOBENEWSWIRE
LIDDS patent covering the NanoZolid® production process granted
28 Sep 2021 //
GLOBENEWSWIRE
LIDDS Interim report January – June 2021
26 Aug 2021 //
GLOBENEWSWIRE
LIDDS – subscription of warrants
06 Jul 2021 //
GLOBENEWSWIRE
Prostate cancer study to be initiated at Uppsala University Hospital
16 Apr 2021 //
PRESS RELEASE
LIDDS and Pharmidea signs manufacturing agreement
25 Feb 2021 //
PRESS RELEASE
European Urology Focus has accepted scientific article describing LIDDS Ph IIb
04 Feb 2021 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.